Immunicum announced the composition of the Nomination Committee on 10 October 2018. As a result of the recent new share issue, the ownership structure has changed and therefore the Nomination Committee for the AGM 2019 has changed, in accordance with the rules of procedure adopted by the AGM.
AP4 is now a part of the Nomination Committe, represented by Jannis Kitsakis, Portfolio Manager.
The other members in the committee are:
- Martin Lindström, Loggen Invest AB
- Johan Sjöström, AP2
- Jamal El-Mosleh, BISP Invest AB
Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, of-the-shelf cell-based therapies. The goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm.